ArticleBMJ open2025
Evaluating a whole-school approach to addressing gender-based violence in Scottish secondary schools (Equally Safe at School): a study protocol for a type I hybrid effectiveness-implementation trial.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEqually Safe at School (ESAS) is a whole-school intervention to reduce gender-based violence (GBV) in secondary school. ESAS comprises self-assessment, student-led action group, two-tier staff training, curriculum enhancement and policy review. Schools set up key activities in Year 1 and embed them in Year 2. GBV, including sexual harassment, is common in secondary schools and disproportionately affects young women and lesbian, gay, bisexual, transgender and queer youth. METHODS AND ANALYSIS: We will evaluate the effectiveness, cost-effectiveness, mechanisms of action and implementation of ESAS. We will recruit 36 schools across Scotland. The evaluation comprises three linked studies:Study 1: Pragmatic cluster randomised trial with 1:1 school allocation to either immediate ESAS intervention start (intervention schools) or 12-month delayed intervention start (control schools). Our primary outcome of student experience of sexual harassment will be measured at 12 months post-randomisation. Analysis of primary and secondary outcomes (student and school level) will be conducted on an intention to treat (ITT) basis comparing schools according to their original allocation.Study 2: Mixed-methods evaluation. Study 2A: Longitudinal follow-up will assess primary, secondary and intermediate outcomes at baseline, 12 months and 24 months of follow-up. Study 2B: Systems and realist-informed process evaluation will assess intervention and control school context, fidelity, dose and reach, acceptability and actor response, and how this varies by school and students. We will also assess implementation processes and mechanisms of action (beneficial or harmful), including if and how change is embedded over time, and if and how ESAS helps schools leverage other assets and resources.Study 3: Economic evaluation to assess the within-trial and longer term cost-effectiveness of ESAS.The methods include surveys in three out of six year groups (Years 2, 4 and 6) in all schools (baseline, 12 months and 24 months of follow-up); interviews with staff, students and other stakeholders; activity observations; brief surveys with key actors and analysis of trial documentation. ETHICS AND DISSEMINATION: Ethical approval by University of Glasgow MVLS Ethics Committee (200220268). Findings will be disseminated via multiple channels to researchers, GBV and education sector stakeholders, study participants and the public. TRIAL REGISTRATION NUMBER: ISRCTN29792495.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.